GLG News by Physicians who Treat Hypertension (US)

Regadenoson is similar to the drug it's set to replace, adenosine, in terms of its ability to increase coronary flow and detect coronary artery disease. However, it's easier to use (it's given as a bolus as opposed to an infusion over 3-5 minutes) and seems to have less side effects. It also has a longer...

The treatment of hyperlipidemia has profound repercussions on cardiovascular disease. The market is huge. I hear that there were 35 million prescriptions for ezetimibe products last year. Although the epidemiological association between LDL and cardiac risk is strong, LDL is an imperfect surrogate for...

The decision by Takeda to halt development of TAK-475, is not surprising considering the problems faced now by companies trying to get regulatory approval for new lipid-lowering drugs. TAK-475 was not more potent, but was thought to have a better safety profile than statins. However, because the safety...

This article brings more visibility to issue of effect of angiogenesis inhibitors on kidney function Other mechanisms of injury have previously been described.  Current case simply adds visibility and more definitive evidence of effect in humans Mechanism described is likely not restricted...

The development of the new technology related to Stereotaxis has been slow going.  While there is much hope there is also much hype.  It is not clear that Stereotaxis really adds much to the success of catheter ablation of atrial fibrillaiton.  There has been a vocal minority...

The field of anticoagulant compounds to be used in the prevention and  treatment of venous and arterial thrombosis is getting more crowded by the day. The new compounds are set to replace coumadin and heparin, to widely used medicines that have some serious disadvantages (heparin has also made...

Plasugrel is an attractive new medication for those patients undergoing cardiac catheterization with subsequent coronary intervention.  However, its niche will be with those patients at lower bleeding risk.  This is due to the fact that in the trial TRITON TIMI 38, prasugrel (which acts via...

Simcor does not remove the major complication that occurs with niacin which is flushing. I do not see this as a successful drug.

Patients with rare malignancies, especially those with already metastatic diseases, are being treated with novel oncologic agents.  However, as is being seen with many drugs, the hemodynamic consequences of these agents, in many cases a rise in blood pressure, may lead to cardiovascular consequences. ...

1:Most of our legislators are forcefully endorsing generic drug usage and importing cheaper drugs.2:As a physician specialist in Clinical Pharmacologist I am fully aware or the safety and efficacy pitfalls of poorly manufactured  drugs and have done clinical research documenting the risks of patients...